Revance Therapeutics, Inc. (RVNC)
| Market Cap | 383.05M |
| Revenue (ttm) | 256.95M +25.8% |
| Net Income | -184.44M |
| EPS | -1.91 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 3.650 |
| Previous Close | 3.650 |
| Day's Range | 3.650 - 3.650 |
| 52-Week Range | 2.300 - 7.560 |
| Beta | 0.95 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 26, 2025 |
About RVNC
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Ph... [Read more]
Financial Performance
In 2023, Revance Therapeutics's revenue was $234.04 million, an increase of 76.55% compared to the previous year's $132.57 million. Losses were -$323.99 million, -9.10% less than in 2022.
Financial StatementsNews
RVNC STOCK NEWS: Robbins LLP Reminds Revance Therapeutics, Inc. Investors of the Pending Lead Plaintiff Deadline – March 4, 2025
SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Revance Therapeutics...
Crown Laboratories Completes Acquisition of Revance Therapeutics
NEW YORK--(BUSINESS WIRE)--Yesterday, Crown Laboratories, Inc. ("Crown"), a Hildred Capital portfolio company and privately held, global innovative leader in the skincare industry, announced the closi...
Crown Laboratories Announces Completion of Acquisition of Revance Therapeutics
The business combination reinforces Crown's position as a leading, innovative, high-growth aesthetics and skincare company JOHNSON CITY, Tenn. , Feb. 6, 2025 /PRNewswire/ -- Crown Laboratories, Inc. (...
Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer
JOHNSON CITY, Tenn. and NASHVILLE, Tenn.
Revance Stockholders Urged to Tender Their Shares in Support of Crown Transaction by the February 4th Deadline
Crown offer of $3.65 per share is the only offer available to Revance stockholders Crown offer unanimously approved by the Revance Board of Directors Teoxane withdraws its previous proposal, says it w...
Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer
JOHNSON CITY & NASHVILLE, Tenn.--(BUSINESS WIRE)--Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer.
Crown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc.
JOHNSON CITY, Tenn. , Jan. 13, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced that, at the request of Rev...
Deadline Approaching: Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming March 4, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who pur...
Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in Cash
Compelling Cash Proposal Provides 16% Premium Over Revance's Amended and Restated Agreement with Crown Laboratories GENEVA , Jan. 6, 2025 /PRNewswire/ -- Teoxane SA today announced that on January 6, ...
REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc. - RVNC
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Revance Therapeu...